封面
市场调查报告书
商品编码
1905192

日本蛋白质疗法市场报告(按产品(单株抗体、人类胰岛素、促红血球生成素、凝血因子、融合蛋白及其他)、治疗领域、功能和地区划分,2026-2034年)

Japan Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2026-2034

出版日期: | 出版商: IMARC | 英文 117 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年,日本蛋白质疗法市场规模达322亿美元。展望未来, IMARC Group预计到2034年,该市场规模将达到542亿美元,2026年至2034年期间的复合年增长率(CAGR)为5.96%。癌症、糖尿病和自体免疫疾病等慢性病发病率的上升,导致对蛋白质疗法的需求增加,以提供标靶有效的治疗,从而推动了市场成长。

本报告解答的关键问题:

  • 日本蛋白质疗法市场目前表现如何?未来几年又将如何发展?
  • 新冠疫情对日本蛋白质疗法市场产生了哪些影响?
  • 日本蛋白质治疗市场依产品类型分類的组成是怎样的?
  • 日本蛋白质治疗市场依治疗领域分類的组成是怎样的?
  • 日本蛋白质治疗市场依功能分類的组成是怎样的?
  • 日本蛋白质治疗市场价值链的各个阶段有哪些?
  • 日本蛋白质疗法的关键驱动因素和挑战是什么?
  • 日本蛋白质疗法市场的结构是怎么样的?主要参与者有哪些?
  • 日本蛋白质治疗药物市场的竞争程度如何?

目录

第一章:序言

第二章:范围与方法

  • 研究目标
  • 利害关係人
  • 数据来源
  • 市场估算
  • 预测方法

第三章:执行概要

第四章:日本蛋白质疗法市场-简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章:日本蛋白质疗法市场概况

  • 历史及当前市场趋势(2020-2025)
  • 市场预测(2026-2034)

第六章:日本蛋白质治疗市场-依产品细分

  • 单株抗体(mAbs)
  • 人类胰岛素
  • 促红血球生成素
  • 凝血因子
  • 融合蛋白
  • 其他的

第七章:日本蛋白质治疗市场-依治疗领域划分

  • 代谢紊乱
  • 免疫系统疾病
  • 血液系统疾病
  • 癌症
  • 荷尔蒙失调
  • 遗传性疾病
  • 其他的

第八章:日本蛋白质治疗市场-按功能细分

  • 酶活性和调节活性
  • 特殊目标活动
  • 疫苗
  • 蛋白质诊断

第九章:日本蛋白质疗法市场-按地区划分

  • 关东地区
  • 关西/近畿地区
  • 中部/中部地区
  • 九州·冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第十章:日本蛋白质疗法市场-竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳制胜策略
  • 竞争格局分析
  • 公司评估象限

第十一章:关键参与者简介

第十二章:日本蛋白质疗法市场-产业分析

  • 驱动因素、限制因素和机会
  • 波特五力分析
  • 价值链分析

第十三章:附录

简介目录
Product Code: SR112026A18904

Japan protein therapeutics market size reached USD 32.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 54.2 Billion by 2034, exhibiting a growth rate (CAGR) of 5.96% during 2026-2034. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has led to an increased demand for protein therapeutics to provide targeted and effective treatment, is driving the market.

Protein therapeutics refers to a class of medical treatments that utilize proteins, typically biologically derived molecules, to prevent, manage, or cure various diseases and medical conditions. These therapeutic proteins can include antibodies, enzymes, hormones, or other functional proteins that play crucial roles in the body's biological processes. Protein therapeutics are designed to target specific disease mechanisms, such as binding to cancer cells or modulating immune responses, offering a high degree of precision and reduced side effects compared to traditional pharmaceuticals. They are often produced using biotechnology techniques, including recombinant DNA technology, and can be administered through injections, infusions, or other delivery methods. Examples of protein therapeutics include monoclonal antibodies used to treat autoimmune diseases like rheumatoid arthritis, insulin for diabetes management, and clotting factors for hemophilia. These therapies have revolutionized medicine, providing effective treatments for a wide range of diseases while continually advancing through ongoing research and development efforts.

Japan Protein Therapeutics Market Trends:

The protein therapeutics market in Japan is thriving due to several key drivers that have propelled its growth. Firstly, advancements in biotechnology have opened up new avenues for the development of protein-based drugs. This is exemplified by the increasing use of recombinant DNA technology, which allows for the production of therapeutic proteins with enhanced specificity and efficacy. Furthermore, the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has driven the demand for innovative treatment options. As a result, pharmaceutical companies are investing heavily in R&D to create novel protein therapeutics targeting these diseases. Additionally, the aging regional population is a significant driver of the protein therapeutics market. With a growing elderly population, there is an increased need for therapies that can address age-related conditions, further bolstering the demand for protein-based drugs. Moreover, the emerging trend toward personalized medicine that tailors treatments to individual patients is expected to drive the protein therapeutics market in Japan during the forecast period.

Japan Protein Therapeutics Market Segmentation:

Product Insights:

  • Monoclonal Antibodies (mAbs)
  • Human Insulin
  • Erythropoietin
  • Clotting Factors
  • Fusion Protein
  • Others

Therapy Area Insights:

  • Metabolic Disorders
  • Immunological Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others

Function Insights:

  • Enzymatic and Regulatory Activity
  • Special Targeting Activity
  • Vaccines
  • Protein Diagnostics

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan protein therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan protein therapeutics market?
  • What is the breakup of the Japan protein therapeutics market on the basis of product?
  • What is the breakup of the Japan protein therapeutics market on the basis of therapy area?
  • What is the breakup of the Japan protein therapeutics market on the basis of function?
  • What are the various stages in the value chain of the Japan protein therapeutics market?
  • What are the key driving factors and challenges in the Japan protein therapeutics?
  • What is the structure of the Japan protein therapeutics market and who are the key players?
  • What is the degree of competition in the Japan protein therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Protein Therapeutics Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Protein Therapeutics Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Protein Therapeutics Market - Breakup by Product

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Human Insulin
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Erythropoietin
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)
  • 6.4 Clotting Factors
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2020-2025)
    • 6.4.3 Market Forecast (2026-2034)
  • 6.5 Fusion Protein
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2020-2025)
    • 6.5.3 Market Forecast (2026-2034)
  • 6.6 Others
    • 6.6.1 Historical and Current Market Trends (2020-2025)
    • 6.6.2 Market Forecast (2026-2034)

7 Japan Protein Therapeutics Market - Breakup by Therapy Area

  • 7.1 Metabolic Disorders
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Immunological Disorders
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Hematological Disorders
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)
  • 7.4 Cancer
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2020-2025)
    • 7.4.3 Market Forecast (2026-2034)
  • 7.5 Hormonal Disorders
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2020-2025)
    • 7.5.3 Market Forecast (2026-2034)
  • 7.6 Genetic Disorders
    • 7.6.1 Overview
    • 7.6.2 Historical and Current Market Trends (2020-2025)
    • 7.6.3 Market Forecast (2026-2034)
  • 7.7 Others
    • 7.7.1 Historical and Current Market Trends (2020-2025)
    • 7.7.2 Market Forecast (2026-2034)

8 Japan Protein Therapeutics Market - Breakup by Function

  • 8.1 Enzymatic and Regulatory Activity
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Special Targeting Activity
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)
  • 8.3 Vaccines
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2020-2025)
    • 8.3.3 Market Forecast (2026-2034)
  • 8.4 Protein Diagnostics
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2020-2025)
    • 8.4.3 Market Forecast (2026-2034)

9 Japan Protein Therapeutics Market - Breakup by Region

  • 9.1 Kanto Region
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Breakup by Product
    • 9.1.4 Market Breakup by Therapy Area
    • 9.1.5 Market Breakup by Function
    • 9.1.6 Key Players
    • 9.1.7 Market Forecast (2026-2034)
  • 9.2 Kansai/Kinki Region
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Breakup by Product
    • 9.2.4 Market Breakup by Therapy Area
    • 9.2.5 Market Breakup by Function
    • 9.2.6 Key Players
    • 9.2.7 Market Forecast (2026-2034)
  • 9.3 Central/ Chubu Region
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Breakup by Product
    • 9.3.4 Market Breakup by Therapy Area
    • 9.3.5 Market Breakup by Function
    • 9.3.6 Key Players
    • 9.3.7 Market Forecast (2026-2034)
  • 9.4 Kyushu-Okinawa Region
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Breakup by Product
    • 9.4.4 Market Breakup by Therapy Area
    • 9.4.5 Market Breakup by Function
    • 9.4.6 Key Players
    • 9.4.7 Market Forecast (2026-2034)
  • 9.5 Tohoku Region
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2020-2025)
    • 9.5.3 Market Breakup by Product
    • 9.5.4 Market Breakup by Therapy Area
    • 9.5.5 Market Breakup by Function
    • 9.5.6 Key Players
    • 9.5.7 Market Forecast (2026-2034)
  • 9.6 Chugoku Region
    • 9.6.1 Overview
    • 9.6.2 Historical and Current Market Trends (2020-2025)
    • 9.6.3 Market Breakup by Product
    • 9.6.4 Market Breakup by Therapy Area
    • 9.6.5 Market Breakup by Function
    • 9.6.6 Key Players
    • 9.6.7 Market Forecast (2026-2034)
  • 9.7 Hokkaido Region
    • 9.7.1 Overview
    • 9.7.2 Historical and Current Market Trends (2020-2025)
    • 9.7.3 Market Breakup by Product
    • 9.7.4 Market Breakup by Therapy Area
    • 9.7.5 Market Breakup by Function
    • 9.7.6 Key Players
    • 9.7.7 Market Forecast (2026-2034)
  • 9.8 Shikoku Region
    • 9.8.1 Overview
    • 9.8.2 Historical and Current Market Trends (2020-2025)
    • 9.8.3 Market Breakup by Product
    • 9.8.4 Market Breakup by Therapy Area
    • 9.8.5 Market Breakup by Function
    • 9.8.6 Key Players
    • 9.8.7 Market Forecast (2026-2034)

10 Japan Protein Therapeutics Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Protein Therapeutics Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix